Effervescent famotidine
This article was originally published in The Tan Sheet
Executive Summary
FDA clears ANDA suitability petition for new dosage form of famotidine 10 mg (J&J/Merck's Pepcid AC) in Nov. 30 letter to Budd Lake, N.J.-based regulatory analyst Thomas Blake. He filed the suitability petition on behalf of an unnamed client Sept. 12, 1997 along with petitions for a two-tablet dose of 5 mg effervescent famotidine and two-tablet effervescent ranitidine containing 37.5 mg per tablet (75 mg total dose, equivalent to Warner-Lambert's Zantac 75) ("The Tan Sheet" Sept. 29, 1997, In Brief). The ranitidine petition was withdrawn after FDA approved Zantac Efferdose Feb. 26 ("The Tan Sheet" March 2, p. 1)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC